Exozymes Inc (EXOZ) Annual Balance Sheets

Annual · GAAP · USD millions
Access EXOZ quarterly Balance Sheets →
The balance sheet figures below highlight longer-term patterns in how Exozymes Inc finances operations and invests in assets.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
(Dec 31 2024)
Assets
Cash & cash equivalent3.04
Cash & Short-term Investments3.00
Grants Receivable, Current0.52
Prepaid Expense And Other Assets Current0.38
Total Current Assets3.94
Equipment/Property/Plant Net0.76
Other Assets, Noncurrent1.27
Operating Lease Right Of Use Asset1.05
Total Assets5.97
Liabilities
Accounts Payable, Current AC1.24
Other Liabilities, Current0.33
Total Current Liabilities1.57
Total Long-term Debt0.00
Other liabilities, Noncurrent1.01
OperatingLeaseLiabilityNoncurrent0.85
Operating Lease Liability Current0.28
Total Liabilities2.57
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock24.50
Retained Earnings / Accumulated Deficit-21.10
Other Equity0.00
Common Stockholder's Equity3.40
Total Stockholder's Equity3.40
Liabilities & Stockholder's Equity5.97
4 historic quarters locked

Sign in to unlock the full Exozymes Inc balance sheet history.

About Exozymes Inc Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 30, 2026
  • Source: form10-k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001493152-26-013563

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License